A Paradigm Shift in Osteoarthritis Management through Biomaterial Innovation and Regenerative Nutraceutical Science.

Osteoarthritis (OA) is the most common chronic degenerative joint disorder affecting millions worldwide and is a leading cause of disability among the elderly population. Despite significant advances in pharmacological management, currently available therapies primarily provide symptomatic relief without reversing cartilage degeneration or restoring joint architecture. Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diacerein-based formulations is frequently associated with gastrointestinal, hepatic, renal, and cardiovascular adverse effects, highlighting the need for safer and more effective alternatives.

Recent advances in biomaterial science have identified Natural Egg Shell Membrane (NESM) as a unique extracellular matrix-derived biomaterial containing multiple collagen types (I, III, V and X), elastin, hyaluronic acid, glycosaminoglycans, glucosamine, and biologically active peptides. Unlike isolated collagen supplements, NESM preserves the natural extracellular matrix architecture, allowing multiple bioactive molecules to function synergistically.

Microcore Research Laboratories India Pvt. Ltd. has pioneered a patented technology to preserve the native structural integrity of NESM, resulting in MuttaiJow Complex®, an advanced biomaterial clinically validated in osteoarthritis patients. This innovation has culminated in JointCore®, a novel nutraceutical formulation combining MuttaiJow Complex®, AKBACORE® (Boswellia serrata extract standardized to 30% AKBA), and CUMINCORE® (96% Curcumin extract). Clinical studies have demonstrated efficacy comparable to conventional diacerein-based therapy while offering an improved safety profile and enhanced gastrointestinal tolerability.

This article reviews the scientific basis of NESM technology, clinical evidence supporting JointCore®, and the future role of biomaterial-based regenerative nutraceuticals in musculoskeletal medicine.

INTRODUCTION

Osteoarthritis is no longer considered merely an age-related disease. It is now recognized as a multifactorial disorder involving chronic inflammation, progressive cartilage degeneration, extracellular matrix destruction, subchondral bone remodeling, oxidative stress, and synovial dysfunction. These pathological changes gradually impair joint function, resulting in chronic pain, stiffness, reduced mobility, and diminished quality of life.

According to the Global Burden of Disease Study, nearly 600 million people worldwide were living with osteoarthritis in 2020, and the number is projected to rise substantially by 2050 due to increasing life expectancy, obesity, sedentary lifestyles, and metabolic disorders. In India alone, arthritis affects more than 210 million people, with osteoarthritis accounting for the majority of cases. Women above the age of 55 years are particularly vulnerable because of hormonal changes associated with menopause, reduced bone density, and altered collagen metabolism.

The socioeconomic impact of osteoarthritis is profound. It is one of the leading causes of disability, work absenteeism, healthcare expenditure, and reduced productivity. As populations continue to age globally, there is an urgent need for therapeutic strategies that not only alleviate symptoms but also preserve joint structure and function.

Traditional pharmacological management largely focuses on pain control using NSAIDs, corticosteroids, glucosamine, chondroitin sulfate, and diacerein. While these agents may reduce inflammation and improve mobility temporarily, they do not regenerate damaged cartilage or restore the extracellular matrix. Long-term administration is often limited by gastrointestinal irritation, hepatotoxicity, nephrotoxicity, and cardiovascular risks. Consequently, clinicians and researchers are increasingly exploring biologically active nutraceuticals capable of modulating disease pathways while maintaining excellent safety profiles.

Among these innovations, Natural Egg Shell Membrane has emerged as one of the most promising biomaterials in regenerative nutraceutical science because of its unique molecular composition and ability to support connective tissue repair.

MICROCORE RESEARCH LABORATORIES: PIONEERING BIOMATERIAL INNOVATION

Founded in 2007, Microcore Research Laboratories India Pvt. Ltd. has established itself as one of India’s leading biotechnology companies dedicated to the development of clinically validated functional biomaterials and advanced nutraceutical ingredients. Under the leadership of M. Chandra Mohan, the company has built an integrated research ecosystem spanning microbiology, biomaterials engineering, nutraceutical formulation, fermentation technology, and translational clinical research.

Recognizing the limitations of conventional nutraceutical ingredients, Microcore embarked on an ambitious mission to develop indigenous biomaterials capable of delivering measurable clinical benefits. Over nearly a decade of intensive research, the company designed and patented a proprietary extraction and stabilization technology that preserves the native extracellular matrix structure of Natural Egg Shell Membrane.

Read More: Click Here